Accident Compensation Corp lessened its stake in Laboratory Corporation of America Holdings (NYSE:LH) by 2.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 40,231 shares of the medical research company’s stock after selling 1,100 shares during the period. Laboratory Corporation of America comprises approximately 1.7% of Accident Compensation Corp’s investment portfolio, making the stock its 19th largest holding. Accident Compensation Corp’s holdings in Laboratory Corporation of America were worth $6,074,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in shares of Laboratory Corporation of America by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 10,361,891 shares of the medical research company’s stock worth $1,597,181,000 after buying an additional 231,600 shares during the period. Boston Partners raised its stake in shares of Laboratory Corporation of America by 0.6% during the 3rd quarter. Boston Partners now owns 4,619,670 shares of the medical research company’s stock worth $697,432,000 after buying an additional 29,298 shares during the period. Nordea Investment Management AB raised its stake in shares of Laboratory Corporation of America by 2.0% during the 2nd quarter. Nordea Investment Management AB now owns 2,696,851 shares of the medical research company’s stock worth $415,693,000 after buying an additional 54,100 shares during the period. FMR LLC raised its stake in shares of Laboratory Corporation of America by 9.4% during the 2nd quarter. FMR LLC now owns 1,780,950 shares of the medical research company’s stock worth $274,516,000 after buying an additional 153,546 shares during the period. Finally, UBS Asset Management Americas Inc. raised its stake in shares of Laboratory Corporation of America by 70.5% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 1,543,126 shares of the medical research company’s stock worth $237,857,000 after buying an additional 637,848 shares during the period. Institutional investors and hedge funds own 91.45% of the company’s stock.

In related news, Director Dwight Gary Gilliland sold 971 shares of the stock in a transaction on Monday, October 30th. The stock was sold at an average price of $153.52, for a total value of $149,067.92. Following the completion of the transaction, the director now directly owns 3,501 shares of the company’s stock, valued at approximately $537,473.52. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.90% of the stock is currently owned by corporate insiders.

Laboratory Corporation of America Holdings (NYSE LH) traded down $2.69 during midday trading on Wednesday, reaching $155.22. The company had a trading volume of 573,400 shares, compared to its average volume of 723,059. Laboratory Corporation of America Holdings has a 1 year low of $123.41 and a 1 year high of $164.22. The company has a current ratio of 1.89, a quick ratio of 1.75 and a debt-to-equity ratio of 1.18. The firm has a market cap of $16,075.24, a P/E ratio of 16.98, a P/E/G ratio of 1.68 and a beta of 0.87.

Laboratory Corporation of America (NYSE:LH) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.46 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.38 by $0.08. Laboratory Corporation of America had a return on equity of 16.75% and a net margin of 7.40%. The firm had revenue of $2.60 billion during the quarter, compared to the consensus estimate of $2.55 billion. During the same period in the prior year, the company earned $2.25 EPS. The firm’s revenue was up 9.5% compared to the same quarter last year. research analysts predict that Laboratory Corporation of America Holdings will post 9.52 EPS for the current fiscal year.

Several research analysts have recently weighed in on the company. Mizuho set a $165.00 target price on Laboratory Corporation of America and gave the stock a “neutral” rating in a research note on Friday, December 1st. ValuEngine raised Laboratory Corporation of America from a “hold” rating to a “buy” rating in a research note on Thursday, November 30th. Jefferies Group set a $167.00 target price on Laboratory Corporation of America and gave the stock a “hold” rating in a research note on Friday, November 24th. Zacks Investment Research downgraded Laboratory Corporation of America from a “buy” rating to a “hold” rating in a research note on Friday, October 27th. Finally, Robert W. Baird reaffirmed a “hold” rating and set a $150.00 target price on shares of Laboratory Corporation of America in a research note on Friday, October 27th. Six research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. Laboratory Corporation of America has an average rating of “Buy” and an average price target of $170.92.

COPYRIGHT VIOLATION WARNING: “Accident Compensation Corp Sells 1,100 Shares of Laboratory Corporation of America Holdings (LH)” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://theolympiareport.com/2017/12/06/accident-compensation-corp-sells-1100-shares-of-laboratory-corporation-of-america-holdings-lh.html.

Laboratory Corporation of America Company Profile

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Institutional Ownership by Quarter for Laboratory Corporation of America (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.